Targeting epigenetic mechanisms in a type of acute leukemia
Combinational Targeting the Feed-forward Epigenetic Circuitry in Mixed Lineage Leukemia
This study is looking at how certain biological processes affect mixed lineage leukemia (MLL-r) and aims to find better treatment options by exploring new combination therapies that target specific enzymes involved in the disease.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11023022 on NIH RePORTER |
What this research studies
This research investigates the role of specific epigenetic mechanisms in mixed lineage leukemia (MLL-r), a type of acute leukemia with poor prognosis. The study focuses on the interaction between the DOT1L enzyme and the PHF20/KAT8 histone acetyltransferase complex, which are crucial for maintaining the expression of oncogenes in this cancer. By exploring combination therapies that target these mechanisms, the research aims to develop more effective treatment options for patients. The methodology includes advanced techniques such as CRISPR for discovering functional elements involved in leukemia progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with MLL-rearranged acute leukemia who have limited treatment options.
Not a fit: Patients with other types of leukemia or those who do not have MLL-rearranged leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective targeted therapies for patients with MLL-rearranged leukemias.
How similar studies have performed: Other research has shown promising results with targeted therapies in similar contexts, indicating potential for success in this novel approach.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Chen, Chun-Wei David — Beckman Research Institute/city of Hope
- Study coordinator: Chen, Chun-Wei David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.